Registro:

Referencias:

• Olayioye, M.A., Beuvink, I., Horsch, K., Daly, J.M., Hynes, N.E., ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases (1999) J Biol Chem, 274, pp. 17209-17218. , 10.1074/jbc.274.24.17209, 10358079
• Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Ullrich, A., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer (1989) Science, 244, pp. 707-712. , 10.1126/science.2470152, 2470152
• Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Norton, L., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 (2001) N Engl J Med, 344, pp. 783-792. , 10.1056/NEJM200103153441101, 11248153
• Hudis, C.A., Trastuzumab-mechanism of action and use in clinical practice (2007) N Engl J Med, 357, pp. 39-51. , 10.1056/NEJMra043186, 17611206
• Nahta, R., Yu, D., Hung, M.C., Hortobagyi, G.N., Esteva, F.J., Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer (2006) Nat Clin Pract Oncol, 3, pp. 269-280. , 10.1038/ncponc0509, 16683005
• Wang, S.C., Lien, H.C., Xia, W., Chen, I.F., Lo, H.W., Wang, Z., Ali-Seyed, M., Hung, M.C., Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2 (2004) Cancer Cell, 6, pp. 251-261. , 10.1016/j.ccr.2004.07.012, 15380516
• Dillon, M.F., Stafford, A.T., Kelly, G., Redmond, A.M., McIlroy, M., Crotty, T.B., McDermott, E., Young, L.S., Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients (2008) Endocr Relat Cancer, 15, pp. 745-753. , 10.1677/ERC-08-0009, 18469157
• Beguelin, W., Diaz Flaque, M.C., Proietti, C.J., Cayrol, F., Rivas, M.A., Tkach, M., Rosemblit, C., Elizalde, P.V., Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3 (2010) Mol Cell Biol, 30, pp. 5456-5472. , 10.1128/MCB.00012-10, 2976427, 20876300
• Sutherland, R.L., Musgrove, E.A., Cyclins and breast cancer (2004) J Mammary Gland Biol Neoplasia, 9, pp. 95-104
• Butt, A.J., Caldon, C.E., McNeil, C.M., Swarbrick, A., Musgrove, E.A., Sutherland, R.L., Cell cycle machinery: links with genesis and treatment of breast cancer (2008) Adv Exp Med Biol, 630, pp. 189-205. , 10.1007/978-0-387-78818-0_12, 18637492
• Singletary, S.E., Allred, C., Ashley, P., Bassett, L.W., Berry, D., Bland, K.I., Borgen, P.I., Greene, F.L., Revision of the American Joint Committee on Cancer staging system for breast cancer (2002) J Clin Oncol, 20, pp. 3628-3636. , 10.1200/JCO.2002.02.026, 12202663
• Page, D.L., Ellis, I.O., Elston, C.W., Histologic grading of breast cancer. Let's do it (1995) Am J Clin Pathol, 103, pp. 123-124
• Wolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., Dowsett, M., Hayes, D.F., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer (2007) Arch Pathol Lab Med, 131, pp. 18-43
• Giuliani, R., Durbecq, V., Di Leo, A., Paesmans, M., Larsimont, D., Leroy, J.Y., Borms, M., Cardoso, F., Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC) (2007) Eur J Cancer, 43, pp. 725-735. , 10.1016/j.ejca.2006.11.019, 17251007
• Upton, G., Fisher's exact test (1992) Journal of the Royal Statistical Society, Series A, 155, pp. 395-402
• Vittinghoff, E., McCulloch, C.E., Relaxing the rule of ten events per variable in logistic and Cox regression (2007) Am J Epidemiol, 165, pp. 710-718. , 10.1093/aje/kwk052, 17182981
• McShane, L.M., Altman, D.G., Sauerbrei, W., Taube, S.E., Gion, M., Clark, G.M., Reporting recommendations for tumor marker prognostic studies (2005) J Clin Oncol, 23, pp. 9067-9072. , 10.1200/JCO.2004.01.0454, 16172462
• Nunes, C.B., Rocha, R.M., Reis-Filho, J.S., Lambros, M.B., Rocha, G.F., Sanches, F.S., Oliveira, F.N., Gobbi, H., Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas (2008) J Clin Pathol, 61, pp. 934-938. , 10.1136/jcp.2007.053892, 18474540
• Proietti, C.J., Rosemblit, C., Beguelin, W., Rivas, M.A., Diaz Flaque, M.C., Charreau, E.H., Schillaci, R., Elizalde, P.V., Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth (2009) Mol Cell Biol, 29, pp. 1249-1265. , 10.1128/MCB.00853-08, 2643818, 19103753
• Lanari, C., Lamb, C.A., Fabris, V.T., Helguero, L.A., Soldati, R., Bottino, M.C., Giulianelli, S., Molinolo, A., The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer (2009) Endocr Relat Cancer, 16, pp. 333-350. , 10.1677/ERC-08-0244, 19190078
• Giri, D.K., Ali-Seyed, M., Li, L.Y., Lee, D.F., Ling, P., Bartholomeusz, G., Wang, S.C., Hung, M.C., Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor (2005) Mol Cell Biol, 25, pp. 11005-11018. , 10.1128/MCB.25.24.11005-11018.2005, 1316946, 16314522
• Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Slamon, D.J., Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer (2003) J Natl Cancer Inst, 95, pp. 142-153. , 10.1093/jnci/95.2.142, 12529347
• Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Botstein, D., Molecular portraits of human breast tumours (2000) Nature, 406, pp. 747-752. , 10.1038/35021093, 10963602
• Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Borresen-Dale, A.L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (2001) Proc Natl Acad Sci USA, 98, pp. 10869-10874. , 10.1073/pnas.191367098, 58566, 11553815
• Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Botstein, D., Repeated observation of breast tumor subtypes in independent gene expression data sets (2003) Proc Natl Acad Sci USA, 100, pp. 8418-8423. , 10.1073/pnas.0932692100, 166244, 12829800
• Cheang, M.C., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Nielsen, T.O., Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer (2009) J Natl Cancer Inst, 101, pp. 736-750. , 10.1093/jnci/djp082, 2684553, 19436038
• Lo, H.W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.F., Hung, M.C., Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer (2005) Cancer Res, 65, pp. 338-348
• Peredo, R., Sastre, G., Serrano, J., Hunter, M.R., Her-2/neu oncogene expression in Puerto Rican females with breast cancer (2001) Cell Mol Biol (Noisy-le-Grand), 47, pp. 1025-1032
• Logullo, A.F., Lopes, A.B., Nonogaki, S., Soares, F.A., Netto, M.M., Nishimoto, I.N., Brentani, M.M., C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer (2007) Oncol Rep, 18, pp. 121-126
• Nagai, M.A., Gerhard, R., Salaorni, S., Fregnani, J.H., Nonogaki, S., Netto, M.M., Soares, F.A., Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer (2010) Int J Oncol, 37, pp. 41-49
• Ross, J.S., Slodkowska, E.A., Symmans, W.F., Pusztai, L., Ravdin, P.M., Hortobagyi, G.N., The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine (2009) Oncologist, 14, pp. 320-368. , 10.1634/theoncologist.2008-0230, 19346299
• Henderson, I.C., Patek, A.J., The relationship between prognostic and predictive factors in the management of breast cancer (1998) Breast Cancer Res Treat, 52, pp. 261-288. , 10.1023/A:1006141703224, 10066087
• Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., Arteaga, C.L., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action (2002) Cancer Res, 62, pp. 4132-4141
• Junttila, T.T., Akita, R.W., Parsons, K., Fields, C., Lewis Phillips, G.D., Friedman, L.S., Sampath, D., Sliwkowski, M.X., Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 (2009) Cancer Cell, 15, pp. 429-440. , 10.1016/j.ccr.2009.03.020, 19411071
• Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Goldhirsch, A., Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer (2009) J Clin Oncol, 27, pp. 5693-5699. , 10.1200/JCO.2009.22.0962, 19884553
• Gonzalez-Angulo, A.M., Litton, J.K., Broglio, K.R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hortobagyi, G.N., High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller (2009) J Clin Oncol, 27, pp. 5700-5706. , 10.1200/JCO.2009.23.2025, 2792998, 19884543
• Press, M.F., Bernstein, L., Thomas, P.A., Meisner, L.F., Zhou, J.Y., Ma, Y., Hung, G., Flom, K.J., HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas (1997) J Clin Oncol, 15, pp. 2894-2904
• Gullick, W.J., Love, S.B., Wright, C., Barnes, D.M., Gusterson, B., Harris, A.L., Altman, D.G., C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes (1991) Br J Cancer, 63, pp. 434-438. , 10.1038/bjc.1991.100, 1971853, 1672253
• Cronin, K.A., Harlan, L.C., Dodd, K.W., Abrams, J.S., Ballard-Barbash, R., Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US (2010) Cancer Invest, 28, pp. 963-968. , 10.3109/07357907.2010.496759, 20690807

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------